Table 2 Spearman’s analysis of correlation between urinary cystatin C and clinical variables (n = 510)

From: Subclinical acute kidney injury is associated with adverse outcomes in critically ill neonates and children

	Initial urinary cystatin C		Peak urinary cystatin C
	Spearman’s r	P value	Spearman’s r	P value
Age, months	-0.230	<0.001	-0.307	<0.001
Body weight, kg	-0.302	<0.001	-0.389	<0.001
Male, n	-0.005	0.904	-0.024	0.589
Illness severity^a, score	0.358	<0.001	0.415	<0.001
MV^b, n	0.087	0.051	0.128	0.004
Duration of MV, days	0.093	0.035	0.141	0.001
AKI^c, n	0.172	<0.001	0.164	<0.001
AKI stage	0.182	<0.001	0.175	<0.001
Severe AKI^d, n	0.197	<0.001	0.196	<0.001
Sepsis^b, n	0.040	0.362	0.065	0.141
Shock/DIC^b, n	0.060	0.173	0.076	0.086
MODS^b, n	0.102	0.021	0.122	0.006
Furosemide^b, n	0.070	0.112	0.127	0.004
Steroid^b, n	-0.020	0.655	-0.005	0.919
Antibiotics^b, n	0.080	0.072	0.106	0.017
Vancomycin^b, n	0.106	0.016	0.121	0.006
Mannitol^b, n	-0.041	0.350	-0.070	0.112
Inotrope^b, n	0.023	0.606	0.034	0.444
Hemofiltration^b, n	0.007	0.880	-0.006	0.898

r = Spearman’s correlation coefficient
AKI acute kidney injury, DIC disseminated intravascular coagulation, ICU intensive care unit, MODS multi-organ dysfunction syndrome, MV mechanical ventilation
^aIllness severity was assessed by the score for neonatal acute physiology in critically ill neonates and the pediatric risk of mortality III score in critically ill children
^bAdministered or developed during ICU stay
^cDeveloped during the first week after ICU admission
^dSevere AKI was defined as Kidney Disease: Improving Global Outcomes (KDIGO) stages 2 and 3

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: maritess.reyes@springernature.com
General enquiries: info@biomedcentral.com